Skip to main content

Folate

Folate (vitamin B9) is a water-soluble B vitamin required for one-carbon metabolism, DNA synthesis, amino-acid homeostasis and epigenetic regulation.[1][2][3] It is the primary carrier of one-carbon units required for de novo synthesis of purines and thymidylate (for DNA replication) and for remethylation of homocysteine to methionine, generating S-adenosylmethionine (SAM), the universal methyl donor.[1][4] Folate deficiency remains clinically relevant despite the US requirement to fortify enriched cereal grain products with folic acid, particularly in pregnancy, alcohol use disorder, and patients on certain medications.[8]

Biochemistry and Metabolism​

Folate is the collective term for vitamin B9 forms, including naturally occurring reduced food folates and folic acid, the synthetic oxidized form used in most supplements and fortified foods.[48] When consumed with food, folic acid is estimated to be at least 85% bioavailable versus about 50% for food folate.[48] After absorption in the proximal jejunum, dietary folate is converted to 5-methyltetrahydrofolate (5-MTHF), the predominant circulating form, which donates its methyl group to homocysteine via the B12-dependent enzyme methionine synthase.[2][3]

Two metabolic outputs depend on folate:

  • Nucleotide synthesis. 5,10-methylenetetrahydrofolate is required by thymidylate synthase for conversion of dUMP to dTMP. Folate deficiency causes uracil misincorporation into DNA, leading to strand breaks and impaired DNA repair.[1][4]
  • Methylation reactions. 5-MTHF feeds the methionine cycle to generate SAM, which methylates DNA, histones, proteins, and lipids. Disruption leads to hyperhomocysteinemia and aberrant DNA methylation.[3][5]

Dietary Sources and Requirements​

Folate occurs naturally in dark green leafy vegetables, legumes, citrus fruits and liver.[50] The RDA for adults is 400 μg dietary folate equivalents (DFE)/day, rising to 600 μg DFE/day in pregnancy.[7][8] The tolerable upper intake level (UL) for folic acid from supplements and fortified foods is 1,000 μg/day, set primarily to avoid masking vitamin B12 deficiency.[7][6]

Since 1998, the US has mandated folic-acid fortification of enriched cereal grain products, which has substantially reduced the prevalence of both folate deficiency and neural tube defects.[7] NHANES 2007–2018 data show median natural-food folate intake of 222 μg DFE/day, below the EAR of 320 μg DFE/day.[8] With fortified foods included, median total intake exceeded the EAR in every demographic group and folate deficiency was uncommon; approximately 2% of adults exceeded the folic-acid UL.[8]

Assessment of Folate Status​

  • Serum folate. The usual initial test when deficiency is suspected; interpret using the local assay and recent intake. A concentration below about 3 ng/mL supports deficiency, but decision limits vary by method and clinical context.[51][9]
  • RBC folate. Reflects longer-term exposure but has analytical limitations and generally adds little to serum testing in routine clinical deficiency assessment. It is not a universally preferred test or an exact analogue of HbA1c.[9]
  • Homocysteine and MMA. Homocysteine may rise in either folate or B12 deficiency. MMA helps assess B12 deficiency because isolated folate deficiency does not usually raise it; renal impairment and coexisting deficiencies complicate interpretation.[10][11]

Causes of Deficiency​

CategoryExamples
Dietary insufficiencyLow intake of vegetables / legumes, alcohol use disorder, poverty, restrictive diets
MalabsorptionCeliac disease, IBD, tropical sprue, short bowel syndrome
Increased demandPregnancy, lactation, hemolytic anemias, exfoliative dermatitis, rapid growth (adolescence)
MedicationsMethotrexate, phenytoin, carbamazepine, valproate, sulfasalazine, trimethoprim; a meta-analysis of 17 studies (2,831 women total) associated oral-contraceptive use with lower plasma folate and, in its 12-study RBC subset (1,389 women), lower RBC folate.[49]
GeneticRare disorders of folate transport/metabolism; common MTHFR variants can modestly influence folate indices but are not, by themselves, a diagnosis of deficiency

Body stores of folate are limited (5–20 mg), and deficiency can develop within 2–4 months of inadequate intake, much faster than B12 deficiency (3–5 years).[9]

Clinical Manifestations​

Hematologic. Folate deficiency can cause megaloblastic anemia with the same hematologic pattern as B12 deficiency: macrocytosis (MCV can exceed 110 fL, although concurrent iron deficiency can leave MCV normal), oval macrocytes, hypersegmented neutrophils and, in severe cases, pancytopenia.[10][11] Unlike B12 deficiency, folate deficiency does not cause subacute combined degeneration, though some evidence suggests folate deficiency may contribute to peripheral neuropathy and neuropsychiatric symptoms in certain patients.[10][12]

Pregnancy complications. Folate deficiency can cause megaloblastic anemia in pregnancy.[13] Beyond anemia, inadequate folate is associated with neural tube defects (NTDs), and may contribute to preeclampsia and other adverse outcomes through hyperhomocysteinemia.[14][15]

Neural Tube Defect Prevention​

The USPSTF 2023 A recommendation is a daily supplement containing 400–800 μg folic acid for people planning to or who could become pregnant, starting at least 1 month before conception and continuing through the first 2–3 months of pregnancy. Its standard-dose recommendation does not cover the highest-risk groups.[16][17]

  • A Cochrane review of five trials found fewer NTDs with periconceptional folate (RR 0.31, 95% CI 0.17–0.58; 6,708 births with outcome information).[14]
  • After a previous NTD-affected pregnancy, CDC recommends 4 mg/day beginning 1 month before conception and through the first 3 months.[44] Arrange a preconception plan for personal or partner NTD history, malabsorption, pregestational diabetes, obesity or other substantial risk; dosing should reflect the specific risk and applicable guidance.[17][18][44]
  • For people with epilepsy using an antiseizure medication, AAN/AES/SMFM 2024 recommends at least 0.4 mg/day before and during pregnancy. The optimal higher dose is uncertain; this does not support automatically prescribing 4 mg to every antiseizure-medication user. Folate does not neutralize valproate's teratogenic risk.[45]

Neural-tube closure usually occurs 26–28 days after fertilization, approximately 6 weeks by obstetric gestational dating, often before pregnancy is recognized. Continue routine prenatal nutrition after the NTD-prevention window.[17]

MTHFR C677T Polymorphism​

Common MTHFR C677T variants can reduce enzyme activity and affect circulating folate and homocysteine. The size of the effect depends on nutritional status and measurement method.[19][20] Among healthy women aged 12–49 years, a meta-analysis of studies using microbiologic assays found serum or plasma and RBC folate approximately 13% and 16% lower, respectively, in TT versus CC participants.[21]

Routine MTHFR testing is not recommended for thrombophilia, recurrent pregnancy loss or related adverse pregnancy outcomes. A common variant does not require avoiding folic acid or substituting methylfolate; CDC confirms that 400 μg/day folic acid raises folate levels regardless of common MTHFR genotype. Rare severe metabolic disorders require specialist evaluation.[22][46]

Folate and Cardiovascular Disease​

Daily folic acid supplementation at 0.5–5 mg typically lowers plasma homocysteine by approximately 25%.[23] Despite strong observational associations between elevated homocysteine and CVD, large RCTs have been largely negative for major cardiovascular events:

  • Trials of homocysteine lowering have not consistently reduced major cardiovascular outcomes.[24]
  • Meta-analysis. A meta-analysis of 30 RCTs (82,334 participants) reported a 10% reduction in stroke (RR 0.90, 95% CI 0.84–0.96) and a 4% reduction in overall CVD (RR 0.96, 0.92–0.99), with greater benefit in lower-baseline-folate populations.[25]

For patients with ischemic stroke or TIA and hyperhomocysteinemia, AHA/ASA 2021 classifies folate, B6 and B12 supplementation as no benefit for preventing subsequent stroke. Treat a documented nutritional deficiency on its own merits; a pooled primary/secondary-prevention signal is not a reason to prescribe vitamins routinely after stroke.[26]

Folate and Cancer​

A dual-modulator hypothesis for folate and colorectal cancer (CRC) proposes that folate sufficiency before lesions develop may suppress carcinogenesis, whereas high folic acid intake after neoplastic foci form may promote progression.[27][28]

  • Observational. Higher total folate intake from foods and supplements is associated with 16% lower CRC risk (RR 0.84, 95% CI 0.80–0.90); the separate estimate for dietary folate from foods alone is 12% lower risk (RR 0.88, 95% CI 0.81–0.96). Dietary-folate analyses also reported inverse associations among alcohol consumers.[27][29][30]
  • Supplementation trials. Folic acid has not reduced adenoma recurrence in RCTs and may increase risk of advanced adenomas and serrated polyps.[28]
  • B-PROOF follow-up. Among 2,524 older trial participants, allocation to folic acid 400 μg plus B12 500 μg/day was associated with overall cancer HR 1.25 (95% CI 1.00–1.53) and CRC HR 1.77 (1.08–2.90). This secondary follow-up of a fracture trial cannot isolate an effect of folic acid alone or be directly extrapolated to routine pregnancy supplementation.[31]

The AGA Clinical Practice Update advises against folic acid supplementation specifically for colorectal-neoplasia prevention; its advice does not oppose indicated deficiency treatment or NTD prevention.[28]

Drug Interactions​

Several drug-folate interactions warrant clinical attention:[32][33][12][34]

  • Methotrexate. Supplement folic or folinic acid during low-dose treatment for non-neoplastic disease according to the prescribing team's regimen. Folate dose and timing vary by regimen; omitting it on methotrexate day is not a universal label requirement. Cancer regimens, including leucovorin rescue after high-dose methotrexate, require protocol-specific timing. Do not add or withhold supplements independently during cancer treatment.[35] For non-neoplastic disease, methotrexate tablets are contraindicated in pregnancy; the label advises contraception during treatment and for 6 months after the final dose for patients who can become pregnant, or 3 months for male patients with partners who can become pregnant.[35] For patients receiving methotrexate, flag its use before anesthesia; the label advises avoiding nitrous oxide because it can potentiate folate-pathway toxicity.[35]

  • Anticonvulsants. Phenytoin, carbamazepine, phenobarbital, primidone increase hepatic folate metabolism and impair intestinal absorption, lowering serum folate. Conversely, folic acid supplementation can antagonize the anticonvulsant action of phenytoin, potentially requiring dose adjustment.[32][33][34]

  • Valproate. Associated with both folate deficiency and teratogenicity (NTD risk); mechanism may involve disruption of the methionine cycle.[36]

  • Alcohol. Alcohol inhibits intestinal absorption, hepatic uptake and metabolic utilization of folate and is an important risk factor for deficiency.[32]

Masking of Vitamin B12 Deficiency — A Critical Safety Concern​

Folic acid alone can correct the anemia of B12 deficiency while neurologic injury continues. Product labeling includes this warning even at doses above 0.1 mg/day; it is a warning against treating B12-deficient anemia with folate alone, not a reason to withhold recommended pregnancy supplementation.[33][34][17]

The often-quoted NHANES odds ratios (4.9 for anemia and 5.0 for cognitive impairment) compared low-B12/high-folate participants with a normal-B12/normal-folate reference group, not with other B12-deficient participants. They describe cross-sectional prevalence associations, not anemia severity or proof that folic acid caused harm.[39] Proposed depletion of active B12 by excess folic acid remains a hypothesis supported mainly by observational, uncontrolled or experimental evidence.[37][38][40][41][42]

Obtain B12 testing before treating unexplained megaloblastic anemia when feasible. If B12 deficiency is suspected, especially with neurologic findings, start B12 promptly and give folate alongside it when needed, rather than delaying treatment while waiting for results.[10][34]

Treatment of Folate Deficiency​

  • A common US regimen is oral folic acid 1 mg/day; adjust duration to hematologic recovery, restoration of intake and the underlying cause. Resistant cases need reassessment for ongoing malabsorption or another diagnosis rather than indefinite dose escalation.[34]
  • After correction, select ongoing supplementation according to continuing risk and pregnancy and bariatric guidance. The adult dietary requirement is not interchangeable with a therapeutic dose.[7][34][43]
  • Treat coexisting or suspected B12 deficiency concurrently. Folate monotherapy is inadequate for B12-related neurologic disease.[10][34]
  • For post-bariatric deficiency, ASMBS recommends 1 mg/day until normalization, then the preventive regimen; routine doses above 1 mg/day are discouraged because of masking risk unless a separate specialist indication applies.[47]

Reconstructive Relevance​

ScenarioPractical action
Pregnancy potential during reconstructive careAsk about reproductive plans, review folic-acid intake and coordinate pregnancy timing with the procedure. Use the standard or high-risk regimen above; an operation does not create a separate folate-dose requirement.[17][44]
Adult congenital/spina bifida carePersonal/partner NTD history warrants preconception counseling. Review antiseizure and potentially teratogenic medicines with their prescribers; folate is not a substitute for medication planning.[15][18][45]
Methotrexate, sulfasalazine, trimethoprim or anticonvulsantsCheck the indication, nutrition, blood counts and interacting medicines. Follow the relevant drug-monitoring and supplementation plan.[32][33][35][36]
Alcohol-related malnutrition or bariatric surgeryAssess the broader nutritional picture and adherence to follow-up; replace likely or established deficits, including B12/thiamine when indicated. Continue scheduled bariatric folate surveillance.[12][43][47]
Ileal diversion or augmentation with macrocytosisEvaluate B12 and other causes before relying on folate. If B12-related neurologic disease is suspected, initiate B12 while completing the work-up.[10]

See Vitamin B12.

See Also​

References​

1. Stover PJ, Garza C. "Bringing Individuality to Public Health Recommendations." The Journal of Nutrition. 2002;132(8 Suppl):2476S–2480S. doi:10.1093/jn/132.8.2476S

2. Balashova OA, Visina O, Borodinsky LN. "Folate action in nervous system development and disease." Developmental Neurobiology. 2018;78(4):391–402. doi:10.1002/dneu.22579

3. Ducker GS, Rabinowitz JD. "One-Carbon Metabolism in Health and Disease." Cell Metabolism. 2017;25(1):27–42. doi:10.1016/j.cmet.2016.08.009

4. Field MS, Kamynina E, Agunloye OC, et al. "Nuclear Enrichment of Folate Cofactors and Methylenetetrahydrofolate Dehydrogenase 1 (MTHFD1) Protect De Novo Thymidylate Biosynthesis During Folate Deficiency." The Journal of Biological Chemistry. 2014;289(43):29642–29650. doi:10.1074/jbc.M114.599589

5. Copp AJ, Stanier P, Greene ND. "Neural Tube Defects: Recent Advances, Unsolved Questions, and Controversies." The Lancet Neurology. 2013;12(8):799–810. doi:10.1016/S1474-4422(13)70110-8

6. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. "Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement." JAMA. 2017;317(2):183–189. doi:10.1001/jama.2016.19438

7. Allen LH. "Micronutrients — Assessment, Requirements, Deficiencies, and Interventions." The New England Journal of Medicine. 2025;392(10):1006–1016. doi:10.1056/NEJMra2314150

8. Zhou Y, Wang A, Yeung LF, et al. "Folate and Vitamin B12 Usual Intake and Biomarker Status by Intake Source in United States Adults Aged ≥ 19 Y: NHANES 2007–2018." The American Journal of Clinical Nutrition. 2023;118(1):241–254. doi:10.1016/j.ajcnut.2023.05.016

9. De Bruyn E, Gulbis B, Cotton F. "Serum and red blood cell folate testing for folate deficiency: new features?" European Journal of Haematology. 2014;92(4):354–359. doi:10.1111/ejh.12237

10. Green R, Datta Mitra A. "Megaloblastic Anemias: Nutritional and Other Causes." The Medical Clinics of North America. 2017;101(2):297–317. doi:10.1016/j.mcna.2016.09.013

11. Provan D, Weatherall D. "Red Cells II: Acquired Anaemias and Polycythaemia." Lancet. 2000;355(9211):1260–1268. doi:10.1016/S0140-6736(00)02099-7

12. Gwathmey KG, Grogan J. "Nutritional neuropathies." Muscle & Nerve. 2020;62(1):13–29. doi:10.1002/mus.26783

13. Committee on Practice Bulletins—Obstetrics. "Anemia in Pregnancy: ACOG Practice Bulletin, Number 233." Obstetrics and Gynecology. 2021;138(2):e55–e64. doi:10.1097/AOG.0000000000004477

14. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. "Effects and Safety of Periconceptional Oral Folate Supplementation for Preventing Birth Defects." Cochrane Database of Systematic Reviews. 2015;(12):CD007950. doi:10.1002/14651858.CD007950.pub3

15. Iskandar BJ, Finnell RH. "Spina Bifida." The New England Journal of Medicine. 2022;387(5):444–450. doi:10.1056/NEJMra2116032

16. Viswanathan M, Urrutia RP, Hudson KN, Middleton JC, Kahwati LC. "Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2023;330(5):460–466. doi:10.1001/jama.2023.9864

17. US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. "Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement." JAMA. 2023;330(5):454–459. doi:10.1001/jama.2023.12876

18. Committee on Practice Bulletins—Obstetrics. "Practice Bulletin No. 187: Neural Tube Defects." Obstetrics and Gynecology. 2017;130(6):e279–e290. doi:10.1097/AOG.0000000000002412

19. Reilly R, McNulty H, Pentieva K, Strain JJ, Ward M. "MTHFR 677TT Genotype and Disease Risk: Is There a Modulating Role for B-Vitamins?" The Proceedings of the Nutrition Society. 2014;73(1):47–56. doi:10.1017/S0029665113003613

20. Bailey LB, Gregory JF. "Polymorphisms of Methylenetetrahydrofolate Reductase and Other Enzymes." The Journal of Nutrition. 1999;129(5):919–922. doi:10.1093/jn/129.5.919

21. Tsang BL, Devine OJ, Cordero AM, et al. "Assessing the Association Between the MTHFR 677C>T Polymorphism and Blood Folate Concentrations: A Systematic Review and Meta-Analysis." The American Journal of Clinical Nutrition. 2015;101(6):1286–1294. doi:10.3945/ajcn.114.099994

22. American College of Medical Genetics and Genomics. "Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2025 revision: A technical standard of the ACMG." Publisher text. See also ACMG MTHFR testing guideline.

23. Kaye AD, Jeha GM, Pham AD, et al. "Folic Acid Supplementation in Patients With Elevated Homocysteine Levels." Advances in Therapy. 2020;37(10):4149–4164. doi:10.1007/s12325-020-01474-z

24. Freeman AM, Morris PB, Aspry K, et al. "A Clinician's Guide for Trending Cardiovascular Nutrition Controversies: Part II." Journal of the American College of Cardiology. 2018;72(5):553–568. doi:10.1016/j.jacc.2018.05.030

25. Li Y, Huang T, Zheng Y, et al. "Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials." Journal of the American Heart Association. 2016;5(8):e003768. doi:10.1161/JAHA.116.003768

26. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. "2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack." Stroke. 2021;52(7):e364–e467. doi:10.1161/STR.0000000000000375

27. Li T, Yin L, Li Y, et al. "Folate Exposures and Risk of Colorectal Cancer: An Umbrella Review of Meta-Analyses of Observational Studies and Randomised Controlled Trials." BMJ Open. 2025;15(11):e103637. doi:10.1136/bmjopen-2025-103637

28. Liang PS, Shaukat A, Crockett SD. "AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review." Clinical Gastroenterology and Hepatology. 2021;19(7):1327–1336. doi:10.1016/j.cgh.2021.02.014

29. Fu H, He J, Li C, Deng Z, Chang H. "Folate Intake and Risk of Colorectal Cancer: A Systematic Review and Up-to-Date Meta-Analysis of Prospective Studies." European Journal of Cancer Prevention. 2023;32(2):103–112. doi:10.1097/CEJ.0000000000000744

30. Khalighi Sikaroudi M, Soltani S, Kolahdouz-Mohammadi R, et al. "The Association Between Dietary Folate Intake and Risk of Colorectal Cancer Incidence: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies." Heliyon. 2024;10(13):e33564. doi:10.1016/j.heliyon.2024.e33564

31. Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, et al. "Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-Term Follow-Up of the B-PROOF Trial." Cancer Epidemiology, Biomarkers & Prevention. 2019;28(2):275–282. doi:10.1158/1055-9965.EPI-17-1198

32. Hesdorffer CS, Longo DL. "Drug-Induced Megaloblastic Anemia." The New England Journal of Medicine. 2015;373(17):1649–1658. doi:10.1056/NEJMra1508861

33. Lambie DG, Johnson RH. "Drugs and Folate Metabolism." Drugs. 1985;30(2):145–155. doi:10.2165/00003495-198530020-00003

34. Rising Pharma. Folic acid tablets: prescribing information. Revised July 2026.

35. Methotrexate tablets: prescribing information. Sections 2 and 5.10; current label checked September 12, 2026.

36. Alonso-Aperte E, Varela-Moreiras G. "Drugs-Nutrient Interactions: A Potential Problem During Adolescence." European Journal of Clinical Nutrition. 2000;54 Suppl 1:S69–S74. doi:10.1038/sj.ejcn.1600989

37. Selhub J, Miller JW, Troen AM, Mason JB, Jacques PF. "Perspective: The High-Folate-Low-Vitamin B-12 Interaction Is a Novel Cause of Vitamin B-12 Depletion With a Specific Etiology — a Hypothesis." Advances in Nutrition. 2022;13(1):16–33. doi:10.1093/advances/nmab106

38. Rashid S, Meier V, Patrick H. "Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent." European Journal of Haematology. 2021;106(4):450–455. doi:10.1111/ejh.13571

39. Selhub J, Morris MS, Jacques PF, Rosenberg IH. "Folate-Vitamin B-12 Interaction in Relation to Cognitive Impairment, Anemia, and Biochemical Indicators of Vitamin B-12 Deficiency." The American Journal of Clinical Nutrition. 2009;89(2):702S–706S. doi:10.3945/ajcn.2008.26947C

40. Miller JW, Smith A, Troen AM, et al. "Excess Folic Acid and Vitamin B12 Deficiency: Clinical Implications?" Food and Nutrition Bulletin. 2024;45(1_suppl):S67–S72. doi:10.1177/03795721241229503

41. Castillo LF, Pelletier CM, Heyden KE, Field MS. "New Insights Into Folate-Vitamin B12 Interactions." Annual Review of Nutrition. 2025. doi:10.1146/annurev-nutr-120524-043056

42. Reynolds EH, Sobczyńska-Malefora A, Green R. "Fortification, Folate and Vitamin B12 Balance, and the Nervous System. Is Folic Acid Excess Potentially Harmful?" European Journal of Clinical Nutrition. 2025. doi:10.1038/s41430-025-01652-8

43. Mechanick JI, Apovian C, Brethauer S, et al. "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures — 2019 Update." Obesity. 2020;28(4):O1–O58. doi:10.1002/oby.22719

44. CDC. About Folic Acid. Updated September 10, 2026; recurrence-prevention section.

45. AAN, AES, SMFM. "Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline." 2024. Full text, recommendation 6.

46. CDC. MTHFR Gene Variant and Folic Acid Facts. July 16, 2026.

47. Parrott J, Frank L, Rabena R, et al. "ASMBS Integrated Health Nutritional Guidelines: 2016 Update, Micronutrients." Surgery for Obesity and Related Diseases. 2017;13:727–741. doi:10.1016/j.soard.2016.12.018. Guideline tables.

48. NIH Office of Dietary Supplements. Folate: Health Professional Fact Sheet. Updated November 30, 2022.

49. Shere M, Bapat P, Nickel C, Kapur B, Koren G. "Association Between Use of Oral Contraceptives and Folate Status: A Systematic Review and Meta-Analysis." J Obstet Gynaecol Can. 2015;37(5):430–438. doi:10.1016/S1701-2163(15)30258-9

50. Institute of Medicine. "8 Folate." Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academies Press; 1998. doi:10.17226/6015

51. Centers for Disease Control and Prevention. NHANES 2011–2012 Folate Microbiologic Assay: Laboratory Procedure Manual.